Johnson & Johnson announced long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI significantly extended overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, reducing the risk of death by 45% versus standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone. With these data, CARVYKTI is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- J&J says Phase 3 CEPHEUS study meets primary endpoint
- Johnson & Johnson announces updated results from Phase 1b RedirecTT-1 study
- Johnson & Johnson provides updated results from Phase 1b TRIMM-2 study
- Johnson & Johnson Subsidiary Files for Bankruptcy to Settle Talc Claims
- Johnson & Johnson subsidiary Red River Talc files for Chapter 11 bankruptcy